Remix does reverse merger with Passage Bio for mRNA degrader
From the article
Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.
Continue reading on endpoints.newsYou might also wanna read
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Bars·4d ago
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Bars·2d ago
Anne Wojcicki's Nonprofit Acquires 23andMe for $305 Million
Anne Wojcicki's nonprofit, TTAM Research Institute, has successfully outbid Regeneron Pharmaceuticals to acquire 23andMe for $305 million, i
cnbc.com·1y agoScribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials
Fierce Biotech·5d ago
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
Bars·4d ago
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
STAT·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.